Achieving cancer cell death with PI3K/mTOR-targeted therapies

Annals of the New York Academy of Sciences

Volumn 1280, Issue 1, 2013, Pages 15-18

  Yea, Sung Su ^a   Fruman, David A ^b  

^a Inje University   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Chemoresistance; MTOR; PI3K

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BENDAMUSTINE; BIM PROTEIN; IDELALISIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVITOCLAX; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN MDM2; PUMA PROTEIN; RITUXIMAB; TRANSCRIPTION FACTOR FOXO; VORINOSTAT; WORTMANNIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DRUG CYTOTOXICITY; HUMAN; LUNG CANCER; NONHUMAN; ONCOLOGY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA;

EID: 84875663689     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12028     Document Type: Article

References (10)

1. Fruman, D.A. & C. Rommel. 2011. PI3Kdelta Inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 1: 562-572.
2. Laplante, M. & D.M. Sabatini. 2012. mTOR Signaling in Growth Control and Disease. Cell 149: 274-293.
3. Engelman, J.A. et al. 2008. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14: 1351-1356.
4. Garcia-Garcia, C. et al. 2012. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 18: 2603-2612.
5. Janes, M.R. et al. 2010. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med. 16: 205-213.
6. Vanhaesebroeck, B. et al. 2010. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11: 329-341.
7. Manning, B.D. & L.C. Cantley. 2007. AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
8. Janes, M.R. et al. 2012. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. doi: 10.1038/leu.2012.276. Oct. 1 [Epub ahead of print].
9. Popovic, R. & J.D. Licht. 2012. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2: 405-413.
10. Davids, M.S. et al. 2012. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 120: 3501-3509.